Drug intelligence / Profile preview

chikungunya virus vaccine (Phylex BioSciences)

Development stage: Preclinical
Lead developer: Phylex BioSciences
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

Phylex BioSciences is developing a preclinical-stage mRNA vaccine candidate for the prevention of Chikungunya virus infection. The vaccine utilizes Phylex's proprietary mRNA self-assembling nanoparticle technology, where the mRNA encodes a viral antigen that is displayed on a self-assembling nanoparticle. This platform is designed using computational analysis and deep learning AI systems to optimize antigen presentation and immune response. The development program is currently in the preclinical phase, with the company pursuing parallel tracks for preclinical-grade and cGMP manufacturing.

Other names: Phylex Chikungunya mRNA vaccine

Beyond the preview

Go deeper on chikungunya virus vaccine (Phylex BioSciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chikungunya virus vaccine (Phylex BioSciences).

Explore the full profile